Trademark: 79192823
Word
AXIOMER
Status Date
Friday, January 12, 2024
Registration Number
5229979
Registration Date
Tuesday, June 27, 2017
Filing Date
Wednesday, March 23, 2016
Published for Opposition
Tuesday, January 10, 2017
Cancellation Date
Friday, January 12, 2024
5 [ Pharmaceutical preparations for the treatment, diagnosis and prevention of genetic diseases and disorders; ] pharmaceutical preparations for the treatment of genetic diseases based on oligonucleotides, [ oligoribonucleotides, aptamers, nucleic acid molecules, dna, ] * for use in * rna [, polynucleotides, ribozymes, mirnas, snornas, mrnas or sirnas ]
1 [ Chemical compounds for scientific or research purposes ]
42 [ Laboratory research services relating to pharmaceuticals; medical research; pharmaceutical research and development; laboratory research and analysis in the field of medicines; services of biotechnological, chemical and pharmacological laboratories, including scientific and technological research, in relation to the production of chemicals and biotechnological products for use in the preparation of pharmaceuticals; development of pharmaceutical preparations and medicines; development of technologies for the production of pharmaceutical semi finished and/or finished preparations; academic research, medical and biochemical research and development services; chemistry, laboratory technicians' and engineering services; research and development in the field of biotechnology; research into and development and testing of pharmaceutical and biochemical semi- finished products, in particular for use in medicines, research into and development and testing of medicines; development of test systems for pharmaceutical, medical and sanitizing preparations; services development and identification of and research into new drug targets ]
In the heading, Int. Cl. 1 and Int. Cl. 42 should be deleted. In the statement line 5 and lines 10-22, should deleted. In the statement, lines 6-9, should be deleted, except "pharmaceutical preparations for the treatment of genetic diseases based on oligonucleotides, rna". In the statement, line 8, before "rna" "for use in" should be inserted.
Color is not claimed as a feature of the mark.
Oct 1, 2016
Sn Assigned For Sect 66a Appl From Ib
Oct 6, 2016
New Application Office Supplied Data Entered
Oct 11, 2016
Application Filing Receipt Mailed
Oct 6, 2016
Assigned To Examiner
Oct 6, 2016
Non-Final Action Written
Oct 7, 2016
Non-Final Action (Ib Refusal) Prepared For Review
Oct 27, 2016
Refusal Processed By Mpu
Oct 27, 2016
Non-Final Action Mailed - Refusal Sent To Ib
Nov 11, 2016
Refusal Processed By Ib
Dec 1, 2016
Teas Response To Office Action Received
Dec 1, 2016
Teas/Email Correspondence Entered
Dec 1, 2016
Correspondence Received In Law Office
Dec 2, 2016
Approved For Pub - Principal Register
May 24, 2017
Extension Of Time To Oppose Process - Terminated
Jun 27, 2017
Registered-Principal Register
Aug 8, 2017
Case Assigned To Post Registration Paralegal
Dec 21, 2016
Notification Of Notice Of Publication E-Mailed
Jan 10, 2017
Published For Opposition
Jan 10, 2017
Official Gazette Publication Confirmation E-Mailed
Feb 6, 2017
Extension Of Time To Oppose Received
Apr 20, 2017
Change Of Name/Address Rec'd From Ib
Jun 23, 2017
Limitation Of Goods Received From Ib
Aug 8, 2017
Correction Under Section 7 - Processed
Sep 27, 2017
Final Disposition Notice Created, To Be Sent To Ib
Sep 28, 2017
Final Disposition Processed
Sep 28, 2017
Final Disposition Notice Sent To Ib
Jun 27, 2022
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Jan 12, 2024
Cancelled Section 71
Sep 13, 2024
Total Invalidation Of Reg Ext Protection Created
Sep 14, 2024
Invalidation Processed
Sep 14, 2024
Total Invalidation Of Reg Ext Protection Sent To Ib
Apr 12, 2018
Invalidation Reviewed - No Action Required By Office
Aug 8, 2017
Limitation From The Ib Examined And Entered
Oct 28, 2017
Final Decision Transaction Processed By Ib
Apr 8, 2018
Partial Invalidation Of Reg Ext Protection Created
Trademark Alertz updated from USPTO on 2030-01-24
